Matt Cooperberg: Good morning, good afternoon, depending on where you are. Welcome to a Zoom edition of the Uro Today Localized Prostate Cancer Center of Excellence. It’s a pleasure to be joined today by Dr. Scott Eggener. Dr. Eggener is the Bruce and Beth White Family Professor of Surgery and Radiology at the University of […]
Patients with cancer have been disproportionally affected by the COVID-19 pandemic. This effect has included the adverse outcomes in patients with cancer who develop COVID-19, the impact of the COVID-19 pandemic on the delivery of cancer care, as well as the severe disruption to cancer research. However, patients with cancer are a heterogeneous patient population […]
Alicia Morgans: Hi, my name is Alicia Morgans and I’m a GU Medical Oncologist and Associate Professor of Medicine at Northwestern University. I’m so excited to have here with me today a friend and colleague Dr. Maha Hussain, who is a Professor of Medicine and a GU Medical Oncologist also at Northwestern University. Thank you […]
Background: Several studies investigating the role of PD-L1 in upper tract urothelial carcinoma (UTUC) patients after radical nephroureterectomy (RNU) to predict prognosis had been published and great controversy existed among them.
We performed data collection concerning the coronavirus disease 2019 (COVID-19) pandemic-related delay in the diagnosis of cancers to individuate proper corrective procedures. A comparison was made among the number of first pathologic diagnoses of malignancy made from weeks 11 to 20 of 2018, 2019, and 2020 at seven anatomic pathology units serving secondary care hospitals […]
Human Kidney Injury Molecule-1 (hKIM-1) was proposed as urinary biomarker of renal cell carcinoma (RCC). The aim of the study was to validate urinary hKIM-1 as a biomarker of RCC. Forty-six participants were enrolled into the study, including 30 patients with clear-cell or papillary RCC and 16 matched patients in the comparison group.
The germ cell supranetwork multidisciplinary team (SMDT) for the Anglian Network covers a population of 7.5 million. We reviewed 10 years of SMDT discussion and categorised them into five domains ((1) overall outcome, (2) chemotherapy regimens-untreated disease and salvage therapy, (3) radiology, (4) pathology and (5) complex cases) to assess the impact of the SMDT.
Renal cell carcinoma (RCC) is the most common type of renal cancer. Long non‑coding RNA (lncRNA) has been reported to play a vital role in the development and progression of various types of cancer type.
To externally validate the R.E.N.A.L., PADUA and SPARE nephrometry scoring systems for use in retroperitoneal RAPN. Nephrometry scores were calculated for 322 consecutive patients receiving retroperitoneal RAPN at a tertiary referral centre from 2017.
Bone metastatic prostate cancer is one of the most common malignancies in developed countries and the second leading cause of cancer-related death in men. There remains no effective treatment for metastatic prostate cancer.
